Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.68 |
| ▸ | HRH1 | P35367 | 6/20 | 0.68 |
| ▸ | HTR2B | P41595 | 5/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.68 |
| ▸ | DRD2 | P14416 | 4/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.68 |
| ▸ | HTR2A | P28223 | 4/20 | 0.68 |
| ▸ | HTR2C | P28335 | 4/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.68 |
| ▸ | DRD3 | P35462 | 4/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.68 |
| ▸ | MC3R | P41968 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655611 | 1.00 | ALDH1A1 (0.71) | ALDH1A1SLC6A2HRH1HTR2BKCNH2 | |
| SCHEMBL6970125 | 1.00 | ALDH1A1 (0.71) | ALDH1A1SLC6A2HRH1HTR2BKCNH2 | |
| SCHEMBL6967536 | 0.88 | SLC6A2 (0.63) | ALDH1A1SLC6A2HRH1HTR2BKCNH2 | |
| SCHEMBL6967533 | 0.88 | SLC6A2 (0.63) | ALDH1A1SLC6A2HRH1HTR2BKCNH2 | |
| SCHEMBL14288478 | 0.82 | SLC6A2 (0.69) | ALDH1A1SLC6A2HRH1HTR2BKCNH2 | |
| SCHEMBL11871057 | 0.81 | SLC6A2 (0.68) | ALDH1A1SLC6A2HRH1HTR2BKCNH2 | |
| SCHEMBL14386490 | 0.81 | LMNA (0.97) | ALDH1A1SLC6A2HRH1HTR2BKCNH2 | |
| Dothiepin SCHEMBL34483 | 0.81 | HRH1 (1.00) | ALDH1A1SLC6A2HRH1HTR2BKCNH2 | |
| Dothiepin SCHEMBL684145 | 0.81 | HRH1 (1.00) | ALDH1A1SLC6A2HRH1HTR2BKCNH2 | |
| Dothiepin SCHEMBL3374653 | 0.81 | HRH1 (1.00) | ALDH1A1SLC6A2HRH1HTR2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2286811-A1 | Chemokine receptor antagonists and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-6329385-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, VIRAL DISEASES AND GASTROINTESTINAL DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| EP-0869954-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF NEUROGENIC INFLAMMATION | NOVO NORDISK AS (DK) | 2001-09-19 | — | — | EP | disclosed |
| US-6133268-A | 1,4-disubstituted piperazines | NOVO NORDISK A/S (DK) | 2000-10-17 | — | — | US | disclosed |
| US-6040302-A | ANTIINFLAMMATORY AGENTS TREATING RHEUMATOID ARTHRITIS, MIGRAINE OR ITCHING, INSULIN RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES MELLITUS AND AGEING-ASSOCIATED OBESITY | NOVO NORDISK A/S (DK) | 2000-03-21 | — | — | US | disclosed |
| US-6004983-A | ANALGESICS; ANTIINFLAMMATORY, ANTIARTHRITIC AND ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DE) | 1999-12-21 | — | — | US | disclosed |
| US-6004961-A | ANTIINFLAMMATORY AGENTS, ANALGESICS; NON-INSULIN-DEPENDENT DIABETES; AGE-RELATED OBESITY; DIBENZO(D,G)(1,3,6)DIOXAZOCINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1999-12-21 | — | — | US | disclosed |
| EP-0934312-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934313-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015548-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
| WO-1998015549-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | ALDH1A1 2010/4885SLC6A2 1060/4885HRH1 507/4885 |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | ALDH1A1 2146/4885SLC6A2 976/4885HRH1 361/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | ALDH1A1 2146/4885SLC6A2 976/4885HRH1 361/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | ALDH1A1 2146/4885SLC6A2 976/4885HRH1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.